Palbociclib: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the [[cyclin-dependent kinases]] CDK4 and CDK6 (see also [[CDK4]]).<ref name="a2">PMID:19874578</ref><ref name="a3">PMID:24369047</ref> See also [https://en.wikipedia.org/wiki/Palbociclib Palbociclib]. | Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the [[cyclin-dependent kinases]] CDK4 and CDK6 (see also [[CDK4]]).<ref name="a2">PMID:19874578</ref><ref name="a3">PMID:24369047</ref> See also [https://en.wikipedia.org/wiki/Palbociclib Palbociclib]. | ||
<scene name='10/1001138/Overall/ | <scene name='10/1001138/Overall/3'>The X-ray co-crystal structure of human CDK6 and Palbociclib</scene> ([[5l2i]]). | ||
<scene name='10/1001138/Binding_site/1'>Palbociclib binding site</scene>. | <scene name='10/1001138/Binding_site/1'>Palbociclib binding site</scene>. | ||
Revision as of 13:48, 11 October 2023
Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6 (see also CDK4).[1][2] See also Palbociclib. (5l2i). .
|
| ||||||||||
ReferencesReferences
- ↑ Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C, Los G, Slamon DJ. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11(5):R77. PMID:19874578 doi:10.1186/bcr2419
- ↑ Rocca A, Farolfi A, Bravaccini S, Schirone A, Amadori D. Palbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer. Expert Opin Pharmacother. 2014 Feb;15(3):407-20. PMID:24369047 doi:10.1517/14656566.2014.870555